Long COVID, ME/CFS, POTS, dysautonomia, post-viral syndrome: making sense of overlapping conditions

When you’re trying to understand what’s happened to you after a viral illness, the terminology is confusing. Long COVID. ME/CFS. POTS. Dysautonomia. Post-viral syndrome. Post-viral fatigue. These terms appear in different contexts, are used by different specialists, and sometimes seem to refer to the same thing and sometimes to different things.

This post attempts to clarify what these terms mean, how they relate to each other, and — most importantly — why the labels matter less than the specific features of what’s happening to an individual patient.

The terms and what they mean

Long COVID

Long COVID (also called post-acute sequelae of COVID-19, or PASC) refers to symptoms persisting or developing after acute COVID-19 infection, typically defined as symptoms continuing beyond 12 weeks from onset. It’s an umbrella term that encompasses an enormous range of presentations — respiratory, cardiovascular, neurological, immunological, and more.

Long COVID is not a diagnosis of a specific mechanism or pathology. It’s a time-based definition: you had COVID, and you still have symptoms. The heterogeneity of long COVID is part of what makes it difficult to study and treat.

Within the long COVID umbrella, certain patterns appear repeatedly:

Fatigue with post-exertional worsening (the ME/CFS-like presentation)
Orthostatic intolerance with tachycardia (the POTS-like presentation)
Cognitive impairment (brain fog)
Breathlessness with normal lung function tests
Various combinations of all of the above

ME/CFS

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a specific clinical syndrome defined by a characteristic symptom pattern, the most diagnostically specific of which is post-exertional malaise (PEM). ME/CFS is not a long COVID term — it pre-dates COVID by decades — but a significant proportion of people with severe long COVID meet ME/CFS diagnostic criteria.

The formal diagnostic criteria for ME/CFS (the 2015 Institute of Medicine criteria are the most widely used) require:

Substantial reduction in activity from pre-illness baseline
Post-exertional malaise (worsening of symptoms following exertion, with delayed onset)
Unrefreshing sleep
Plus at least one of: cognitive impairment or orthostatic intolerance

ME/CFS has historically been mismanaged and under-recognised. It’s now understood to be a biologically real disorder with measurable physiological abnormalities, not a psychological condition.

POTS

Postural orthostatic tachycardia syndrome (POTS) is diagnosed when heart rate increases by at least 30 bpm on standing (sustained for 10 minutes), without significant orthostatic hypotension, accompanied by symptoms of orthostatic intolerance. It’s a specific physiological diagnosis, not an umbrella term.

POTS can occur in the context of ME/CFS, long COVID, or independently. It has its own diagnostic criteria and its own treatment pathways. Many people with long COVID develop what is recognised as POTS; others have sub-threshold orthostatic tachycardia that doesn’t meet criteria but causes identical symptoms.

Dysautonomia

Dysautonomia is the broadest of these terms: it refers to dysfunction of the autonomic nervous system in any form. POTS is one type of dysautonomia. Orthostatic hypotension is another. Small fibre neuropathy with autonomic involvement is another. Inappropriate sinus tachycardia is another.

Many people use “dysautonomia” as a general label for post-viral autonomic dysfunction when a more specific diagnosis hasn’t been pinned down, or when the picture has features of several different types. It’s accurate but imprecise.

Post-viral syndrome

“Post-viral syndrome” or “post-viral fatigue syndrome” is the term for fatigue and symptoms persisting after a viral illness, where the syndrome doesn’t meet criteria for a more specific diagnosis. It’s often used before a full diagnostic workup has been done, or when the presentation is early and evolving.

It’s a useful label for “something happened after that virus and it hasn’t resolved” — but it doesn’t specify whether the mechanism is autonomic, immunological, neurological, or some combination.

How these overlap

The overlaps are extensive:

Long COVID is an umbrella. Within it are people whose illness most closely resembles ME/CFS, people whose illness most closely resembles POTS, people with both, and people with neither of these specific patterns but other complications.

ME/CFS and POTS frequently coexist. Orthostatic intolerance is one of the possible features of ME/CFS criteria, and a large proportion of ME/CFS patients also meet POTS criteria. The two conditions share some pathophysiological mechanisms (autonomic dysfunction, reduced circulating volume, small fibre neuropathy) and can require treatment that addresses both.

Post-viral syndrome often evolves into more specific diagnoses. Someone labelled with post-viral fatigue at six months may be diagnosed with ME/CFS at twelve months when the post-exertional pattern becomes clearer, or with POTS when a tilt table test is done.

Dysautonomia is both specific and general. POTS is a specific type of dysautonomia. But “autonomic dysfunction” as a broader feature is present in ME/CFS, long COVID, and many post-viral presentations regardless of whether they meet POTS criteria.

Why the labels matter less than the features

Given this overlap, the practical approach for individual patients is to focus on what is actually happening rather than which label fits best:

What are the symptoms? Fatigue, orthostatic intolerance, cognitive impairment, breathlessness, pain, sleep problems — identifying which of these is present and dominant matters for treatment.

Is there post-exertional malaise? This single feature most determines how exercise and activity should be managed. Graded exercise rehabilitation is appropriate for some post-viral conditions; for those with PEM, it can cause harm. Establishing whether PEM is present should be one of the first questions.

What is the heart rate doing? Elevated resting heart rate, orthostatic tachycardia, and impaired heart rate variability all point toward autonomic dysfunction regardless of whether criteria for a specific diagnosis are met.

What investigations have been done? Tilt table testing or active stand test for orthostatic tachycardia; CPET for exercise intolerance; autonomic function tests for broader autonomic dysfunction. These tests provide data that are clinically useful regardless of diagnostic label.

For a deeper explanation of the physiology, see What’s actually going on: a plain-language guide to post-viral autonomic dysfunction.

What to do with the label question

If you’ve been given one of these diagnoses and you’re trying to understand what it means in relation to the others:

The diagnosis you receive depends significantly on which specialist you saw, what investigations they did, and what their particular framing is. A cardiologist who tilts you and finds 30+ bpm rise will call it POTS. A general physician who sees fatigue and post-exertional worsening may say ME/CFS or post-viral fatigue. A neurologist may say dysautonomia. These can all be describing the same underlying biology.

For tracking and monitoring purposes, the specific label matters less than knowing your key metrics: resting heart rate, orthostatic heart rate change, heart rate variability, and functional capacity. These are the things to track and manage, whatever the diagnosis says at the top of the letter. The COMPASS-31 is a free online questionnaire that measures autonomic symptom burden across six domains and is widely used in dysautonomia research.

The evidence on HRV as a tracking metric is worth reading regardless of which specific label you have — it’s relevant across the full range of post-viral autonomic dysfunction.

The prognosis question

“Will I get better?” is the question everyone with one of these conditions wants answered, and the honest answer is that it depends heavily on which condition, how severe, how long it’s been, and individual factors that aren’t well characterised yet.

What the evidence does show:

Many people with POTS improve over time, particularly with appropriate treatment
ME/CFS is more variable — a significant proportion improve, especially those with shorter illness duration; some reach a stable plateau; some deteriorate
Long COVID is too recent for long-term outcome data, but early cohort studies suggest gradual improvement in many patients over 1–2 years, with a subset remaining substantially affected
The post-viral conditions as a group are more likely to improve with appropriate management (including pacing and autonomic treatment) than without it

References

Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: an overview. Diabetes Metab Syndr. 2021;15(3):869–875.

Bateman L, Bested AC, Bonilla H, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: essentials of diagnosis and management. Mayo Clin Proc. 2021;96(11):2861–2878.

Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular Society position statement on postural orthostatic tachycardia syndrome (POTS) and related disorders of chronic orthostatic intolerance. Can J Cardiol. 2020;36(3):357–372.

Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–146.

Komaroff AL, Bateman L. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front Med (Lausanne). 2021;7:606824.